近日，礼来宣布FDA已批准Zepbound（tirzepatide）治疗肥胖人群的中度至重度阻塞性睡眠呼吸暂停（OSA）的新适应症。在使用Zepbound的同时，应减少热量饮食并增加体育锻炼。OSA适应症的获批，让礼来在与目前最强劲的对手诺和诺德的竞 ...

FDA快讯2024年12月20日，美国食品药品监督管理局（FDA）官网发布消息：FDA已正式批准替尔泊肽（tirzepatide）用于治疗成年肥胖患者的中度至重度阻塞性睡眠呼吸暂停（OSA），与低热量饮食和运动相结合。这也意味着替尔泊肽成为首款OSA ...

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

The US FDA has approved the anti-diabetic drug Zepbound (Tirzepatide) for managing obstructive sleep apnea (OSA) in obese ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

T he weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Sally ...

Eli Lilly’s weight-loss drug tirzepatide has become the first drug for obstructive sleep apnea, a common but serious sleep ...